Search This Blog

Friday, June 12, 2026

'Iranian MP criticizes parliament media over leaked draft on Iran-US talks'

 

Meisam Zohurian, an Iranian lawmaker, said on Friday a text published by the official media outlet of Iran’s parliament on a reported Iran-US agreement draft was “irresponsible” on multiple grounds.

"First, the text includes incorrect claims, such as the recognition of enrichment or the payment of Iran's funds at the outset of the agreement, which are not present in the actual text and effectively create a public perception of the text that will lead to dissatisfaction once the main text is released," he posted on X.

"Second, its publication prompted objections from the opposing side, resulting in the denial by Iran's Foreign Minister, which Trump interpreted as an apology from Iran," Zohurian added.


https://www.iranintl.com/en/liveblog/202606062776

US forces shoot down multiple Iranian one-way attack drones - Reuters

 

US forces shot down multiple Iranian one-way attack drones that were heading toward the Strait of Hormuz, according to Reuters, citing a person familiar with the matter.

'Qatar Tried Secret Deal-Making With Iran To Protect World's Largest Gas Complex'

 By the middle of March during Trump's Operation Epic Fury, Iran was flexing its retaliatory might, and the Gulf region was shocked to see the largest natural-gas production facility in the world, Qatar's North Field, badly damaged - with a key section forced offline and severely damaged.

The Washington Post has just provided some new information which has come to light, writing that "There was an additional, hidden consequence. The strike also dashed secret efforts by Qatar to keep its gas complex, known as Ras Laffan, off Iran’s target list, according to Middle Eastern security officials and Western officials briefed on the intelligence."

Doha skyline file image

This after the punishing Iranian strikes (against a nearby Arab state which hosts US forces) "destroyed sections of a plant that provides nearly a fifth of the globe’s gas supply, imperiled multibillion-dollar contracts with China and other clients, and damaged the prospects of finding an earlier end to the war by dragging Qatar, a key mediator between the United States and Iran, into the fight" - WaPo also reviewed.

That 'secret negotiations' were being held apart from the US - or also separately from other Gulf Cooperation Council (GCC) states is indeed significant, highlighting a theme that Tehran continues to seek to assert leverage by forcing nations to come make side deals - even as the Islamic Republic comes under US bombs and Western pressure.

If it is indeed accurate that Gulf nations are approaching Iran to do individual separate deals, this is for now a diplomatic 'win' for Tehran. Separate deal-making, peeling others away from a united front and bloc, gives Iran some greater leverage and also flexibility in terms of potential post-war economic and political detente with regional states.

The UAE, it was reported earlier this week in Bloomberg, has also reportedly reached its own 'understanding' with the Iranians after some backroom dealing and diplomacy.

"Senior national security officials from the United Arab Emirates and Iran held a face-to-face meeting for the first time since the start of the US-Israeli war against Tehran, according to people with knowledge of the situation," Bloomberg reported

"This week’s meeting marked a stark turnaround for both sides and comes amid their growing acknowledgment of the importance of calmer bilateral ties, the people said, asking not to be named discussing sensitive matters," the report indicated.

Perhaps in both Qatar's and UAE's thinking, there's too much to risk while facing Iran's significant ballistic missile and drone arsenal, at a moment Washington has failed to clearly define an end game, but instead is climbing up the escalation ladder with a cornered and thus fierce Iran, which sees itself fighting for its very survival.

Qatar's effort apparently failed to a large degree, while curiously there's of late been a lack of Iranian targeting on UAE - even as other US-allied countries, namely Kuwait, Bahrain, and Jordan have this week seen new missile waves launched on them.

But possibly Qatar has protected itself from further harm. It too has not been a prime renewed target of Iran's ballistic missiles this week, alongside the Emirates.

https://www.zerohedge.com/geopolitical/qatar-tried-secret-deal-making-iran-protect-worlds-largest-gas-complex

Globe And Mail Caught Pushing Anti-Musk "Hate" Propaganda, Then Quietly Alters Headline

 Summary:

  • Globe And Mail Changes Headline After X post Ratioed 
  • "Reckless Propaganda": Globe And Mail Op-Ed Tells Readers "How To Properly Hate" Elon Musk Ahead Of SpaceX IPO

Globe And Mail Alters Headline 

The hostile, juvenile, and editorially reckless propaganda, amplified by The Globe and Mail in the form of a Thursday op-ed just before the SpaceX IPO earlier today, had to be walked back after viral blowback.

That headline, which no sane editor would ever publish, and we really thought we were past the period of spreading hate by the lefty community, but apparently not at The Globe and Mail, came after the outlet published an op-ed titled: "Opinion: SpaceX IPO makes Elon Musk the first trillionaire. Here's how to properly hate him."

"The previous headline on this article did not meet The Globe's editorial standard. It has been replaced," the Canadian outlet wrote. Yet the outlet has yet to delete the X post and instead changed the headline to: "SpaceX is set to make Elon Musk the first trillionaire. Is that a bad look for capitalism?"

X user Enguerrand VII de Coucy, featured in the Community Notes section on The Globe and Mail's X post, wrote:

They changed "Here's how to properly hate him" to "Is that a bad look for capitalism?" which a) doesn't even make sense and b) isn't fooling anybody. They said what they meant with the original headline, it just "didn't meet their standards" because they usually try to hide their actual feelings she motives more carefully.

"The important thing to remember when reading hostile Canadian media attacks on American individuals or causes is that the Globe and Mail, CBC, etc. are all funded by their government," X user Overton Defenestration said.

"Fomenting hate was not accidental. Your publication continues to trash its reputation," X user Rowan said. 

The Canadian newspaper's anti-Musk propaganda echoed similar rhetoric from unhinged Democrats, left-wing unions, and dark-money-funded NGOs, all of whom now see Musk's trillionaire status as a threat to their power because he will likely divert some of that wealth to fund pro-America movements challenging their progressive empire, which is built on a house of socialist cards.

"Reckless Propaganda": Globe And Mail Op-Ed Tells Readers "How To Properly Hate" Elon Musk Ahead Of SpaceX IPO

Whether it is Elizabeth Warren, left-leaning unions, or Democrat-aligned NGOs funded by dark money, the common pattern here has been an information campaign aimed at Elon Musk to derail the SpaceX IPO. Their motives are very simple: if the game is about power and money, then Musk potentially becoming the world's first trillionaire on Friday morning represents a direct threat to the progressive empire they have built.

Just as with President Trump, the left has mounted a permanent pressure campaign of 'useful idiots' against Elon Musk because he has poured tens of millions of dollars into political campaigns for pro-America candidates - something Democrats, socialists, and Marxists despise. Then, Musk headed up DOGE in early 2025, which resulted in the defunding of USAID - another move by Musk that caused unhinged left-wing NGOs and Democrats to lose their minds.

The anti-Musk crowd was at it again on Thursday, one day before the SpaceX IPO was set to kick off, when a former Wall Street Journal reporter published an opinion piece in The Globe and Mail titled, "SpaceX is set to make Elon Musk the first trillionaire. Here's how to properly hate him."

Chris Gay, who appears to have a lot of pent-up hatred for Musk, began the op-ed: "Now that the SpaceX initial public offering is making Elon Musk all but officially the world's first trillionaire, is it okay to despise him just for being one? To broaden the question: are the billionaires associated with widening inequality a bad look for capitalism?"

The op-ed is less about wealth itself and more of a political framing exercise that uses the SpaceX IPO as the catalyst to recast Musk's soaring fortune as a governance risk. Gay attempts to launder what appears to be hatred toward Musk, centering his argument on democracy, inequality, and political capture. In other words, the target is not simply Musk becoming the world's first trillionaire, but the perceived threat that his capital, influence, and political alignment pose to the progressive establishment's grip on institutional power.

Gay wrote, "By donating at least US$250-million to the Trump campaign in 2024, this private citizen positioned himself to kill a congressional budget deal more or less single-handedly, and then to create a bogus federal agency: the "Department" of Government Efficiency. He staffed it with college-age technobrats who among other things effectively dismantled the U.S. Agency for International Development, which millions of people depended upon for life-critical assistance."

Gay's op-ed, which The Globe and Mail posted on X, was heavily ratioed and had a Community Note ... 

Here's what X users said in response:

It's not just Globe And Mail, the globalist Financial Times pushes the information operation to paint Musk as 'evil' ... 

The left is losing its mind as the nation progresses forward with pro-American innovation and wokeness dies in darkness. 

https://www.zerohedge.com/political/reckless-propaganda-and-mail-op-ed-tells-readers-how-properly-hate-elon-musk-ahead

UAE denies reports of Iran fund transfer

 The United Arab Emirates (UAE) Ministry of Foreign Affairs rejected reports alleging the transfer of funds to Iran, including claims of $3 billion.

The ministry said the claims published by international outlets were "entirely false and unfounded," urging media organizations to verify information and avoid circulating unconfirmed allegations.

https://breakingthenews.net/Article/UAE-denies-reports-of-Iran-fund-transfer/66499414

Some US states said to launch OpenAI probe

 OpenAI Inc. is facing a new inquiry from a coalition of state attorneys general over concerns tied to its business practices, The Wall Street Journal reported, citing people familiar with the matter.

OpenAI received a subpoena from New York Attorney General Letitia James on Friday seeking records related to advertising, consumer engagement, data practices, health information, treatment of minors and seniors, deep learning models, model sycophancy and company policies, according to the Journal.

https://breakingthenews.net/Article/Some-US-states-said-to-launch-OpenAI-probe/66499438

Trial: Vitamin K Supplement Curbs Coronary Atherosclerosis

 

  • A Dutch trial tested the effects of taking the vitamin K homologue menaquinone-7 (MK-7) on measures of atherosclerosis.
  • The study showed a small but statistically significant slowing of coronary artery calcification progression after 1 and 2 years of daily MK-7 supplementation.
  • In particular, results showed slower calcification in noncalcified plaques, though the clinical significance of this remains unknown.

Menaquinone-7 (MK-7) supplementation modestly slowed the progression of coronary artery calcification (CAC) for patients in the placebo-controlled VitaK-CAC trial.

Among people with existing chronic coronary atherosclerosis, CT-derived CAC scores rose to varying degrees between people randomized to the vitamin K homologue or matching placebo, going from 135 AU and 145 AU at baseline, respectively, to 150 AU and 173 AU after 1 year, then finally to 184 AU and 214 AU after 2 years (P=0.02).

Similarly, calcium mass favored those who got once-daily MK-7 supplements: from a baseline level of 25 mg and 26 mg, respectively, calcium mass rose to 28 mg and 33 mg after 1 year and ultimately reached 32 mg and 38 mg after 2 years (P=0.02), reported Peter de Leeuw, MD, PhD, of Maastricht University Medical Center in the Netherlands, and colleagues in JAMA Cardiology.

"The present data support our hypothesis that supplementation with MK-7 during a period of 2 years attenuates coronary artery calcification in individuals with symptomatic CAD [coronary artery disease]. However, the overall effect is modest, and given that the percentage of fast progressors did not differ between the two treatment groups, the clinical significance of our findings remains to be demonstrated," the authors wrote.

"Only the results of a well-designed outcome trial can provide an answer to the question as to whether the effect of MK-7 is beneficial," they cautioned.

The menaquinones, also known as vitamin K2, are a family of compounds synthesized by gut bacteria and thought to aid in bone health and cardiovascular health. MK-7 in particular has been shown to be a powerful inhibitor of vascular calcification, with good bioavailability and a relatively long half-life, hence its attractiveness as a supplement for heart protection.

Coupled with CT angiography data, the present results showed that the benefit of MK-7 supplementation seemed limited to reining in the calcification of early to moderately developed noncalcified plaques, whereas it had no effect on CAC progression in advanced plaque or on de novo atherogenesis.

MK-7 treatment also showed no effect on degree of stenosis or number of affected vessels.

VitaK-CAC investigators argued that the true efficacy of MK-7 may have been underestimated in the study, however, noting that study participants had about 80% adherence to their assigned treatment and a 17% dropout rate. What's more, they were not equipped to study the tiniest calcium deposits in atherosclerotic plaque.

"MK-7 has been suggested to structurally shift macrocalcifications, detectable by CT, to microcalcifications, subtle changes that are not detectable at the plaque level with routine CAC-protocol noncontrast cardiac CT," explained Michael Blaha, MD, MPH, and Sungwoo Choi, MD, MPH, both of the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease in Baltimore, in an accompanying editorial.

"Given what is known about plaque-level calcium density, it is difficult to surmise what the impact on future cardiovascular events might be," they wrote.

The editorialists stressed the need for more research and cited important questions that remain unanswered regarding MK-7's effects on atherosclerosis and cardiovascular health.

"Would MK-7 reduce acute coronary syndromes by slowing early propagation of coronary calcification, reducing the mechanical instability thought to be associated with early calcifications? Would MK-7 increase risk by interfering with later plaque stabilization, reversing the favorable process we associate with statin treatment? Or would there be no effect at all since calcification is largely a byproduct along the continuum of plaque development?" Blaha and Choi posed.

VitaK-CAC was a relatively small study conducted at two centers in the Netherlands. Included were 180 symptomatic patients, with CAC scores of 50-400 AU, who were randomized to MK-7 (360 μg daily) or placebo.

Baseline characteristics were statistically similar between groups. Participants had a median age around 60 years and were 42% women. Statin use was reported in 78%, and the average LDL cholesterol level was 77 mg/dL.

Plasma levels of MK-7 rose significantly in the active treatment group (median 0.50 μg/L to 6.56 μg/L, P<0.001), but not among controls.

No significant adverse effects were associated with MK-7 supplements.

The researchers noted that dietary vitamin K consumption had not been tracked for study participants, but was presumably unchanged given the stability in vitamin K1 levels.

Disclosures

The study was supported by the Dutch Heart Foundation. Nattopharma/Gnosis by Lesaffre provided the MK-7 tablets.

De Leeuw disclosed no relevant conflicts. One co-author disclosed receiving grants from Gnosis by Lesaffre and holding shares in Coagulation Profile outside the submitted work.

Blaha reported grants from the NIH, FDA, American Heart Association, Amgen, Novo Nordisk, and Bayer and personal fees from Novo Nordisk, Bayer, Novartis, Merck, Boehringer Ingelheim, New Amsterdam, Genentech, Eli Lilly, Idorsia, and Scene Health.

Choi disclosed no relevant conflicts.